nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—hematologic cancer	0.463	1	CbGaD
Octreotide—MPO—Cisplatin—hematologic cancer	0.00695	1	CbGbCtD
Octreotide—SSTR5—Signaling by GPCR—IL2—hematologic cancer	2.35e-05	0.000133	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PDGFRA—hematologic cancer	2.35e-05	0.000133	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MTOR—hematologic cancer	2.35e-05	0.000133	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PIK3CB—hematologic cancer	2.35e-05	0.000133	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TERT—hematologic cancer	2.34e-05	0.000132	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—JAK1—hematologic cancer	2.34e-05	0.000132	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PRKCG—hematologic cancer	2.34e-05	0.000132	CbGpPWpGaD
Octreotide—Mental disorder—Epirubicin—hematologic cancer	2.33e-05	6.6e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—FN1—hematologic cancer	2.32e-05	0.000131	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CD80—hematologic cancer	2.32e-05	0.000131	CbGpPWpGaD
Octreotide—Rash—Cisplatin—hematologic cancer	2.32e-05	6.57e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—KIT—hematologic cancer	2.32e-05	0.000131	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CG—hematologic cancer	2.32e-05	0.000131	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—NRAS—hematologic cancer	2.32e-05	0.000131	CbGpPWpGaD
Octreotide—Dermatitis—Cisplatin—hematologic cancer	2.32e-05	6.56e-05	CcSEcCtD
Octreotide—Erythema—Epirubicin—hematologic cancer	2.32e-05	6.56e-05	CcSEcCtD
Octreotide—Malnutrition—Epirubicin—hematologic cancer	2.32e-05	6.56e-05	CcSEcCtD
Octreotide—Diarrhoea—Etoposide—hematologic cancer	2.31e-05	6.53e-05	CcSEcCtD
Octreotide—Anorexia—Prednisone—hematologic cancer	2.3e-05	6.52e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—BAD—hematologic cancer	2.3e-05	0.00013	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NFKBIA—hematologic cancer	2.3e-05	0.00013	CbGpPWpGaD
Octreotide—Ill-defined disorder—Methotrexate—hematologic cancer	2.3e-05	6.5e-05	CcSEcCtD
Octreotide—Tinnitus—Doxorubicin—hematologic cancer	2.3e-05	6.5e-05	CcSEcCtD
Octreotide—Anaemia—Methotrexate—hematologic cancer	2.29e-05	6.48e-05	CcSEcCtD
Octreotide—Feeling abnormal—Betamethasone—hematologic cancer	2.29e-05	6.47e-05	CcSEcCtD
Octreotide—Feeling abnormal—Dexamethasone—hematologic cancer	2.29e-05	6.47e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PDGFB—hematologic cancer	2.29e-05	0.000129	CbGpPWpGaD
Octreotide—Flushing—Doxorubicin—hematologic cancer	2.28e-05	6.47e-05	CcSEcCtD
Octreotide—Cardiac disorder—Doxorubicin—hematologic cancer	2.28e-05	6.47e-05	CcSEcCtD
Octreotide—Flatulence—Epirubicin—hematologic cancer	2.28e-05	6.46e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PTPN11—hematologic cancer	2.28e-05	0.000129	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NOTCH1—hematologic cancer	2.27e-05	0.000129	CbGpPWpGaD
Octreotide—Tension—Epirubicin—hematologic cancer	2.27e-05	6.43e-05	CcSEcCtD
Octreotide—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.27e-05	6.42e-05	CcSEcCtD
Octreotide—Gastrointestinal pain—Betamethasone—hematologic cancer	2.27e-05	6.42e-05	CcSEcCtD
Octreotide—Hypersensitivity—Triamcinolone—hematologic cancer	2.25e-05	6.38e-05	CcSEcCtD
Octreotide—Nervousness—Epirubicin—hematologic cancer	2.25e-05	6.37e-05	CcSEcCtD
Octreotide—Back pain—Epirubicin—hematologic cancer	2.24e-05	6.34e-05	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—HRAS—hematologic cancer	2.24e-05	0.000127	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TSC2—hematologic cancer	2.23e-05	0.000126	CbGpPWpGaD
Octreotide—Malaise—Methotrexate—hematologic cancer	2.23e-05	6.32e-05	CcSEcCtD
Octreotide—Dizziness—Etoposide—hematologic cancer	2.23e-05	6.31e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CD80—hematologic cancer	2.23e-05	0.000126	CbGpPWpGaD
Octreotide—Muscle spasms—Epirubicin—hematologic cancer	2.23e-05	6.3e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—PIK3CG—hematologic cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—KIT—hematologic cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—NRAS—hematologic cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—Immune system disorder—Doxorubicin—hematologic cancer	2.22e-05	6.3e-05	CcSEcCtD
Octreotide—Vertigo—Methotrexate—hematologic cancer	2.22e-05	6.29e-05	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—MAPK3—hematologic cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CREB1—hematologic cancer	2.21e-05	0.000125	CbGpPWpGaD
Octreotide—Urticaria—Dexamethasone—hematologic cancer	2.2e-05	6.24e-05	CcSEcCtD
Octreotide—Urticaria—Betamethasone—hematologic cancer	2.2e-05	6.24e-05	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.2e-05	6.23e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—CDKN1B—hematologic cancer	2.2e-05	0.000124	CbGpPWpGaD
Octreotide—Dizziness—Prednisolone—hematologic cancer	2.2e-05	6.23e-05	CcSEcCtD
Octreotide—Arrhythmia—Doxorubicin—hematologic cancer	2.2e-05	6.23e-05	CcSEcCtD
Octreotide—Asthenia—Triamcinolone—hematologic cancer	2.19e-05	6.21e-05	CcSEcCtD
Octreotide—Body temperature increased—Dexamethasone—hematologic cancer	2.19e-05	6.21e-05	CcSEcCtD
Octreotide—Abdominal pain—Betamethasone—hematologic cancer	2.19e-05	6.21e-05	CcSEcCtD
Octreotide—Abdominal pain—Dexamethasone—hematologic cancer	2.19e-05	6.21e-05	CcSEcCtD
Octreotide—Body temperature increased—Betamethasone—hematologic cancer	2.19e-05	6.21e-05	CcSEcCtD
Octreotide—Nausea—Cisplatin—hematologic cancer	2.19e-05	6.19e-05	CcSEcCtD
Octreotide—Insomnia—Prednisone—hematologic cancer	2.19e-05	6.19e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—IL2RA—hematologic cancer	2.19e-05	0.000124	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PTPN11—hematologic cancer	2.19e-05	0.000124	CbGpPWpGaD
Octreotide—Vision blurred—Epirubicin—hematologic cancer	2.18e-05	6.18e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—BRAF—hematologic cancer	2.18e-05	0.000123	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—AKT1—hematologic cancer	2.18e-05	0.000123	CbGpPWpGaD
Octreotide—Alopecia—Doxorubicin—hematologic cancer	2.18e-05	6.16e-05	CcSEcCtD
Octreotide—Paraesthesia—Prednisone—hematologic cancer	2.17e-05	6.14e-05	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—IL2—hematologic cancer	2.17e-05	0.000123	CbGpPWpGaD
Octreotide—Pruritus—Triamcinolone—hematologic cancer	2.16e-05	6.13e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—TERT—hematologic cancer	2.16e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCL2—hematologic cancer	2.16e-05	0.000122	CbGpPWpGaD
Octreotide—Cough—Methotrexate—hematologic cancer	2.16e-05	6.11e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—CASP3—hematologic cancer	2.16e-05	0.000122	CbGpPWpGaD
Octreotide—Mental disorder—Doxorubicin—hematologic cancer	2.16e-05	6.11e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—IL6R—hematologic cancer	2.15e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IL2—hematologic cancer	2.15e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CREBBP—hematologic cancer	2.15e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—FGFR3—hematologic cancer	2.15e-05	0.000122	CbGpPWpGaD
Octreotide—Ill-defined disorder—Epirubicin—hematologic cancer	2.15e-05	6.08e-05	CcSEcCtD
Octreotide—Convulsion—Methotrexate—hematologic cancer	2.14e-05	6.07e-05	CcSEcCtD
Octreotide—Vomiting—Etoposide—hematologic cancer	2.14e-05	6.07e-05	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—IL6—hematologic cancer	2.14e-05	0.000121	CbGpPWpGaD
Octreotide—Malnutrition—Doxorubicin—hematologic cancer	2.14e-05	6.07e-05	CcSEcCtD
Octreotide—Erythema—Doxorubicin—hematologic cancer	2.14e-05	6.07e-05	CcSEcCtD
Octreotide—Anaemia—Epirubicin—hematologic cancer	2.14e-05	6.06e-05	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—MAPK3—hematologic cancer	2.13e-05	0.00012	CbGpPWpGaD
Octreotide—Agitation—Epirubicin—hematologic cancer	2.13e-05	6.03e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—MAPK14—hematologic cancer	2.13e-05	0.00012	CbGpPWpGaD
Octreotide—Dyspepsia—Prednisone—hematologic cancer	2.13e-05	6.02e-05	CcSEcCtD
Octreotide—Rash—Etoposide—hematologic cancer	2.13e-05	6.02e-05	CcSEcCtD
Octreotide—Dermatitis—Etoposide—hematologic cancer	2.12e-05	6.01e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CREB1—hematologic cancer	2.12e-05	0.00012	CbGpPWpGaD
Octreotide—Headache—Etoposide—hematologic cancer	2.11e-05	5.98e-05	CcSEcCtD
Octreotide—Flatulence—Doxorubicin—hematologic cancer	2.11e-05	5.98e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—PDGFB—hematologic cancer	2.11e-05	0.000119	CbGpPWpGaD
Octreotide—Myalgia—Methotrexate—hematologic cancer	2.11e-05	5.97e-05	CcSEcCtD
Octreotide—Chest pain—Methotrexate—hematologic cancer	2.11e-05	5.97e-05	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—hematologic cancer	2.11e-05	5.97e-05	CcSEcCtD
Octreotide—Tension—Doxorubicin—hematologic cancer	2.1e-05	5.95e-05	CcSEcCtD
Octreotide—Decreased appetite—Prednisone—hematologic cancer	2.1e-05	5.95e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—CCND1—hematologic cancer	2.1e-05	0.000119	CbGpPWpGaD
Octreotide—Rash—Prednisolone—hematologic cancer	2.1e-05	5.94e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—JUN—hematologic cancer	2.1e-05	0.000119	CbGpPWpGaD
Octreotide—Dermatitis—Prednisolone—hematologic cancer	2.1e-05	5.93e-05	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.09e-05	5.92e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—BRAF—hematologic cancer	2.09e-05	0.000118	CbGpPWpGaD
Octreotide—Malaise—Epirubicin—hematologic cancer	2.09e-05	5.91e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—ESR1—hematologic cancer	2.09e-05	0.000118	CbGpPWpGaD
Octreotide—Fatigue—Prednisone—hematologic cancer	2.08e-05	5.9e-05	CcSEcCtD
Octreotide—Headache—Prednisolone—hematologic cancer	2.08e-05	5.9e-05	CcSEcCtD
Octreotide—Discomfort—Methotrexate—hematologic cancer	2.08e-05	5.89e-05	CcSEcCtD
Octreotide—Nervousness—Doxorubicin—hematologic cancer	2.08e-05	5.89e-05	CcSEcCtD
Octreotide—Vertigo—Epirubicin—hematologic cancer	2.08e-05	5.89e-05	CcSEcCtD
Octreotide—Syncope—Epirubicin—hematologic cancer	2.08e-05	5.88e-05	CcSEcCtD
Octreotide—Back pain—Doxorubicin—hematologic cancer	2.07e-05	5.87e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CCL2—hematologic cancer	2.07e-05	0.000117	CbGpPWpGaD
Octreotide—Constipation—Prednisone—hematologic cancer	2.07e-05	5.85e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—IL6R—hematologic cancer	2.07e-05	0.000117	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CREBBP—hematologic cancer	2.06e-05	0.000117	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—FN1—hematologic cancer	2.06e-05	0.000117	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TSC2—hematologic cancer	2.06e-05	0.000117	CbGpPWpGaD
Octreotide—Muscle spasms—Doxorubicin—hematologic cancer	2.06e-05	5.83e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—MAP2K1—hematologic cancer	2.05e-05	0.000116	CbGpPWpGaD
Octreotide—Palpitations—Epirubicin—hematologic cancer	2.05e-05	5.79e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PIK3CD—hematologic cancer	2.04e-05	0.000115	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NFKBIA—hematologic cancer	2.04e-05	0.000115	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—BAD—hematologic cancer	2.04e-05	0.000115	CbGpPWpGaD
Octreotide—Loss of consciousness—Epirubicin—hematologic cancer	2.04e-05	5.76e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—CDKN1A—hematologic cancer	2.03e-05	0.000115	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PTEN—hematologic cancer	2.03e-05	0.000115	CbGpPWpGaD
Octreotide—Dizziness—Triamcinolone—hematologic cancer	2.02e-05	5.73e-05	CcSEcCtD
Octreotide—Cough—Epirubicin—hematologic cancer	2.02e-05	5.72e-05	CcSEcCtD
Octreotide—SSTR3—GPCR downstream signaling—PIK3CA—hematologic cancer	2.02e-05	0.000114	CbGpPWpGaD
Octreotide—Anaphylactic shock—Methotrexate—hematologic cancer	2.02e-05	5.72e-05	CcSEcCtD
Octreotide—Vision blurred—Doxorubicin—hematologic cancer	2.02e-05	5.72e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—NOTCH1—hematologic cancer	2.02e-05	0.000114	CbGpPWpGaD
Octreotide—Convulsion—Epirubicin—hematologic cancer	2.01e-05	5.68e-05	CcSEcCtD
Octreotide—Infection—Methotrexate—hematologic cancer	2.01e-05	5.68e-05	CcSEcCtD
Octreotide—Nausea—Etoposide—hematologic cancer	2e-05	5.67e-05	CcSEcCtD
Octreotide—Hypertension—Epirubicin—hematologic cancer	2e-05	5.66e-05	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—KRAS—hematologic cancer	2e-05	0.000113	CbGpPWpGaD
Octreotide—Feeling abnormal—Prednisone—hematologic cancer	1.99e-05	5.64e-05	CcSEcCtD
Octreotide—Asthenia—Dexamethasone—hematologic cancer	1.99e-05	5.64e-05	CcSEcCtD
Octreotide—Asthenia—Betamethasone—hematologic cancer	1.99e-05	5.64e-05	CcSEcCtD
Octreotide—Ill-defined disorder—Doxorubicin—hematologic cancer	1.99e-05	5.63e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—FGFR3—hematologic cancer	1.98e-05	0.000112	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MAPK8—hematologic cancer	1.98e-05	0.000112	CbGpPWpGaD
Octreotide—Nervous system disorder—Methotrexate—hematologic cancer	1.98e-05	5.61e-05	CcSEcCtD
Octreotide—Anaemia—Doxorubicin—hematologic cancer	1.98e-05	5.61e-05	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—AKT1—hematologic cancer	1.98e-05	0.000112	CbGpPWpGaD
Octreotide—Thrombocytopenia—Methotrexate—hematologic cancer	1.98e-05	5.6e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—CD80—hematologic cancer	1.98e-05	0.000112	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Prednisone—hematologic cancer	1.98e-05	5.6e-05	CcSEcCtD
Octreotide—Nausea—Prednisolone—hematologic cancer	1.98e-05	5.59e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PIK3CG—hematologic cancer	1.97e-05	0.000112	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KIT—hematologic cancer	1.97e-05	0.000112	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—NRAS—hematologic cancer	1.97e-05	0.000112	CbGpPWpGaD
Octreotide—Arthralgia—Epirubicin—hematologic cancer	1.97e-05	5.58e-05	CcSEcCtD
Octreotide—Chest pain—Epirubicin—hematologic cancer	1.97e-05	5.58e-05	CcSEcCtD
Octreotide—Myalgia—Epirubicin—hematologic cancer	1.97e-05	5.58e-05	CcSEcCtD
Octreotide—Agitation—Doxorubicin—hematologic cancer	1.97e-05	5.58e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—MAP2K1—hematologic cancer	1.97e-05	0.000111	CbGpPWpGaD
Octreotide—Anxiety—Epirubicin—hematologic cancer	1.96e-05	5.56e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—MAPK14—hematologic cancer	1.96e-05	0.000111	CbGpPWpGaD
Octreotide—Pruritus—Betamethasone—hematologic cancer	1.96e-05	5.56e-05	CcSEcCtD
Octreotide—Pruritus—Dexamethasone—hematologic cancer	1.96e-05	5.56e-05	CcSEcCtD
Octreotide—Skin disorder—Methotrexate—hematologic cancer	1.96e-05	5.55e-05	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.96e-05	5.54e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—PIK3CD—hematologic cancer	1.96e-05	0.000111	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—FGF2—hematologic cancer	1.95e-05	0.00011	CbGpPWpGaD
Octreotide—Hyperhidrosis—Methotrexate—hematologic cancer	1.95e-05	5.53e-05	CcSEcCtD
Octreotide—Discomfort—Epirubicin—hematologic cancer	1.95e-05	5.52e-05	CcSEcCtD
Octreotide—Vomiting—Triamcinolone—hematologic cancer	1.94e-05	5.51e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PTPN11—hematologic cancer	1.94e-05	0.00011	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.94e-05	0.00011	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EP300—hematologic cancer	1.93e-05	0.000109	CbGpPWpGaD
Octreotide—Malaise—Doxorubicin—hematologic cancer	1.93e-05	5.47e-05	CcSEcCtD
Octreotide—Rash—Triamcinolone—hematologic cancer	1.93e-05	5.46e-05	CcSEcCtD
Octreotide—Dry mouth—Epirubicin—hematologic cancer	1.93e-05	5.46e-05	CcSEcCtD
Octreotide—Dermatitis—Triamcinolone—hematologic cancer	1.93e-05	5.45e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PIK3R1—hematologic cancer	1.93e-05	0.000109	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ESR1—hematologic cancer	1.93e-05	0.000109	CbGpPWpGaD
Octreotide—Vertigo—Doxorubicin—hematologic cancer	1.93e-05	5.45e-05	CcSEcCtD
Octreotide—Anorexia—Methotrexate—hematologic cancer	1.93e-05	5.45e-05	CcSEcCtD
Octreotide—Syncope—Doxorubicin—hematologic cancer	1.92e-05	5.44e-05	CcSEcCtD
Octreotide—Urticaria—Prednisone—hematologic cancer	1.92e-05	5.44e-05	CcSEcCtD
Octreotide—Headache—Triamcinolone—hematologic cancer	1.92e-05	5.42e-05	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—KRAS—hematologic cancer	1.91e-05	0.000108	CbGpPWpGaD
Octreotide—Abdominal pain—Prednisone—hematologic cancer	1.91e-05	5.41e-05	CcSEcCtD
Octreotide—Body temperature increased—Prednisone—hematologic cancer	1.91e-05	5.41e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—FN1—hematologic cancer	1.9e-05	0.000108	CbGpPWpGaD
Octreotide—Diarrhoea—Dexamethasone—hematologic cancer	1.9e-05	5.38e-05	CcSEcCtD
Octreotide—Diarrhoea—Betamethasone—hematologic cancer	1.9e-05	5.38e-05	CcSEcCtD
Octreotide—Palpitations—Doxorubicin—hematologic cancer	1.89e-05	5.36e-05	CcSEcCtD
Octreotide—Oedema—Epirubicin—hematologic cancer	1.89e-05	5.35e-05	CcSEcCtD
Octreotide—Anaphylactic shock—Epirubicin—hematologic cancer	1.89e-05	5.35e-05	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—MAPK3—hematologic cancer	1.89e-05	0.000107	CbGpPWpGaD
Octreotide—Loss of consciousness—Doxorubicin—hematologic cancer	1.88e-05	5.33e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—NFKBIA—hematologic cancer	1.88e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—BAD—hematologic cancer	1.88e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—SRC—hematologic cancer	1.88e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CREB1—hematologic cancer	1.88e-05	0.000106	CbGpPWpGaD
Octreotide—Infection—Epirubicin—hematologic cancer	1.88e-05	5.32e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—FGF2—hematologic cancer	1.87e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—JAK2—hematologic cancer	1.87e-05	0.000106	CbGpPWpGaD
Octreotide—Cough—Doxorubicin—hematologic cancer	1.87e-05	5.29e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—NOTCH1—hematologic cancer	1.86e-05	0.000105	CbGpPWpGaD
Octreotide—Shock—Epirubicin—hematologic cancer	1.86e-05	5.26e-05	CcSEcCtD
Octreotide—Convulsion—Doxorubicin—hematologic cancer	1.86e-05	5.26e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—BRAF—hematologic cancer	1.85e-05	0.000105	CbGpPWpGaD
Octreotide—Nervous system disorder—Epirubicin—hematologic cancer	1.85e-05	5.25e-05	CcSEcCtD
Octreotide—Thrombocytopenia—Epirubicin—hematologic cancer	1.85e-05	5.24e-05	CcSEcCtD
Octreotide—Hypertension—Doxorubicin—hematologic cancer	1.85e-05	5.24e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—PIK3R1—hematologic cancer	1.85e-05	0.000104	CbGpPWpGaD
Octreotide—Tachycardia—Epirubicin—hematologic cancer	1.84e-05	5.22e-05	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.84e-05	5.21e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—CCL2—hematologic cancer	1.84e-05	0.000104	CbGpPWpGaD
Octreotide—Skin disorder—Epirubicin—hematologic cancer	1.84e-05	5.2e-05	CcSEcCtD
Octreotide—Dizziness—Dexamethasone—hematologic cancer	1.84e-05	5.2e-05	CcSEcCtD
Octreotide—Dizziness—Betamethasone—hematologic cancer	1.84e-05	5.2e-05	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—PIK3CA—hematologic cancer	1.83e-05	0.000104	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IL6R—hematologic cancer	1.83e-05	0.000104	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—VEGFA—hematologic cancer	1.83e-05	0.000104	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CREBBP—hematologic cancer	1.83e-05	0.000103	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MDM2—hematologic cancer	1.83e-05	0.000103	CbGpPWpGaD
Octreotide—Hyperhidrosis—Epirubicin—hematologic cancer	1.83e-05	5.17e-05	CcSEcCtD
Octreotide—Insomnia—Methotrexate—hematologic cancer	1.83e-05	5.17e-05	CcSEcCtD
Octreotide—Myalgia—Doxorubicin—hematologic cancer	1.82e-05	5.17e-05	CcSEcCtD
Octreotide—Arthralgia—Doxorubicin—hematologic cancer	1.82e-05	5.17e-05	CcSEcCtD
Octreotide—Chest pain—Doxorubicin—hematologic cancer	1.82e-05	5.17e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—CD80—hematologic cancer	1.82e-05	0.000103	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CG—hematologic cancer	1.82e-05	0.000103	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KIT—hematologic cancer	1.82e-05	0.000103	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—NRAS—hematologic cancer	1.82e-05	0.000103	CbGpPWpGaD
Octreotide—Anxiety—Doxorubicin—hematologic cancer	1.82e-05	5.15e-05	CcSEcCtD
Octreotide—Nausea—Triamcinolone—hematologic cancer	1.82e-05	5.14e-05	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—hematologic cancer	1.81e-05	5.13e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—STAT3—hematologic cancer	1.81e-05	0.000103	CbGpPWpGaD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.81e-05	5.13e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—NRAS—hematologic cancer	1.81e-05	0.000102	CbGpPWpGaD
Octreotide—Discomfort—Doxorubicin—hematologic cancer	1.8e-05	5.1e-05	CcSEcCtD
Octreotide—Anorexia—Epirubicin—hematologic cancer	1.8e-05	5.1e-05	CcSEcCtD
Octreotide—Dyspnoea—Methotrexate—hematologic cancer	1.8e-05	5.1e-05	CcSEcCtD
Octreotide—Somnolence—Methotrexate—hematologic cancer	1.8e-05	5.08e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—JAK2—hematologic cancer	1.79e-05	0.000101	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PTPN11—hematologic cancer	1.79e-05	0.000101	CbGpPWpGaD
Octreotide—Dry mouth—Doxorubicin—hematologic cancer	1.78e-05	5.05e-05	CcSEcCtD
Octreotide—Hypersensitivity—Prednisone—hematologic cancer	1.78e-05	5.04e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—MTOR—hematologic cancer	1.78e-05	0.000101	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CB—hematologic cancer	1.78e-05	0.000101	CbGpPWpGaD
Octreotide—Dyspepsia—Methotrexate—hematologic cancer	1.78e-05	5.03e-05	CcSEcCtD
Octreotide—Vomiting—Betamethasone—hematologic cancer	1.76e-05	5e-05	CcSEcCtD
Octreotide—Vomiting—Dexamethasone—hematologic cancer	1.76e-05	5e-05	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—PIK3CA—hematologic cancer	1.76e-05	9.95e-05	CbGpPWpGaD
Octreotide—Decreased appetite—Methotrexate—hematologic cancer	1.76e-05	4.97e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—MDM2—hematologic cancer	1.75e-05	9.91e-05	CbGpPWpGaD
Octreotide—Rash—Dexamethasone—hematologic cancer	1.75e-05	4.95e-05	CcSEcCtD
Octreotide—Rash—Betamethasone—hematologic cancer	1.75e-05	4.95e-05	CcSEcCtD
Octreotide—Anaphylactic shock—Doxorubicin—hematologic cancer	1.75e-05	4.95e-05	CcSEcCtD
Octreotide—Oedema—Doxorubicin—hematologic cancer	1.75e-05	4.95e-05	CcSEcCtD
Octreotide—Dermatitis—Dexamethasone—hematologic cancer	1.75e-05	4.95e-05	CcSEcCtD
Octreotide—Dermatitis—Betamethasone—hematologic cancer	1.75e-05	4.95e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—MAP2K1—hematologic cancer	1.75e-05	9.87e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—MAPK3—hematologic cancer	1.74e-05	9.86e-05	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.74e-05	4.94e-05	CcSEcCtD
Octreotide—Fatigue—Methotrexate—hematologic cancer	1.74e-05	4.93e-05	CcSEcCtD
Octreotide—Headache—Dexamethasone—hematologic cancer	1.74e-05	4.92e-05	CcSEcCtD
Octreotide—Headache—Betamethasone—hematologic cancer	1.74e-05	4.92e-05	CcSEcCtD
Octreotide—Infection—Doxorubicin—hematologic cancer	1.74e-05	4.92e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PIK3CD—hematologic cancer	1.73e-05	9.81e-05	CbGpPWpGaD
Octreotide—Asthenia—Prednisone—hematologic cancer	1.73e-05	4.91e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—CREB1—hematologic cancer	1.73e-05	9.8e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MAPK3—hematologic cancer	1.73e-05	9.79e-05	CbGpPWpGaD
Octreotide—Pain—Methotrexate—hematologic cancer	1.73e-05	4.89e-05	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.72e-05	4.88e-05	CcSEcCtD
Octreotide—Shock—Doxorubicin—hematologic cancer	1.72e-05	4.87e-05	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—PIK3CA—hematologic cancer	1.72e-05	9.71e-05	CbGpPWpGaD
Octreotide—Nervous system disorder—Doxorubicin—hematologic cancer	1.72e-05	4.86e-05	CcSEcCtD
Octreotide—Thrombocytopenia—Doxorubicin—hematologic cancer	1.71e-05	4.85e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—BRAF—hematologic cancer	1.71e-05	9.68e-05	CbGpPWpGaD
Octreotide—Pruritus—Prednisone—hematologic cancer	1.71e-05	4.84e-05	CcSEcCtD
Octreotide—Insomnia—Epirubicin—hematologic cancer	1.71e-05	4.84e-05	CcSEcCtD
Octreotide—Tachycardia—Doxorubicin—hematologic cancer	1.71e-05	4.83e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—MTOR—hematologic cancer	1.7e-05	9.64e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CB—hematologic cancer	1.7e-05	9.64e-05	CbGpPWpGaD
Octreotide—Skin disorder—Doxorubicin—hematologic cancer	1.7e-05	4.81e-05	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—KRAS—hematologic cancer	1.7e-05	9.6e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—HRAS—hematologic cancer	1.7e-05	9.6e-05	CbGpPWpGaD
Octreotide—Paraesthesia—Epirubicin—hematologic cancer	1.7e-05	4.81e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—CCL2—hematologic cancer	1.7e-05	9.59e-05	CbGpPWpGaD
Octreotide—Hyperhidrosis—Doxorubicin—hematologic cancer	1.69e-05	4.79e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—IL6R—hematologic cancer	1.69e-05	9.56e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CREBBP—hematologic cancer	1.69e-05	9.55e-05	CbGpPWpGaD
Octreotide—Dyspnoea—Epirubicin—hematologic cancer	1.69e-05	4.77e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—MYC—hematologic cancer	1.68e-05	9.53e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TGFB1—hematologic cancer	1.68e-05	9.5e-05	CbGpPWpGaD
Octreotide—Somnolence—Epirubicin—hematologic cancer	1.68e-05	4.76e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—CDKN1B—hematologic cancer	1.67e-05	9.44e-05	CbGpPWpGaD
Octreotide—Anorexia—Doxorubicin—hematologic cancer	1.67e-05	4.72e-05	CcSEcCtD
Octreotide—Feeling abnormal—Methotrexate—hematologic cancer	1.66e-05	4.71e-05	CcSEcCtD
Octreotide—Dyspepsia—Epirubicin—hematologic cancer	1.66e-05	4.71e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—FGF2—hematologic cancer	1.66e-05	9.39e-05	CbGpPWpGaD
Octreotide—Diarrhoea—Prednisone—hematologic cancer	1.65e-05	4.68e-05	CcSEcCtD
Octreotide—Gastrointestinal pain—Methotrexate—hematologic cancer	1.65e-05	4.68e-05	CcSEcCtD
Octreotide—SSTR3—GPCR downstream signaling—AKT1—hematologic cancer	1.65e-05	9.33e-05	CbGpPWpGaD
Octreotide—Nausea—Betamethasone—hematologic cancer	1.65e-05	4.67e-05	CcSEcCtD
Octreotide—Nausea—Dexamethasone—hematologic cancer	1.65e-05	4.67e-05	CcSEcCtD
Octreotide—Decreased appetite—Epirubicin—hematologic cancer	1.64e-05	4.65e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PIK3R1—hematologic cancer	1.64e-05	9.26e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CASP3—hematologic cancer	1.64e-05	9.25e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IL2—hematologic cancer	1.63e-05	9.23e-05	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.63e-05	4.62e-05	CcSEcCtD
Octreotide—Fatigue—Epirubicin—hematologic cancer	1.63e-05	4.61e-05	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—HRAS—hematologic cancer	1.63e-05	9.2e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—IL6—hematologic cancer	1.62e-05	9.19e-05	CbGpPWpGaD
Octreotide—Pain—Epirubicin—hematologic cancer	1.62e-05	4.58e-05	CcSEcCtD
Octreotide—Constipation—Epirubicin—hematologic cancer	1.62e-05	4.58e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—MAP2K1—hematologic cancer	1.61e-05	9.11e-05	CbGpPWpGaD
Octreotide—Urticaria—Methotrexate—hematologic cancer	1.6e-05	4.54e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—PIK3CD—hematologic cancer	1.6e-05	9.05e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CDKN1B—hematologic cancer	1.6e-05	9.05e-05	CbGpPWpGaD
Octreotide—Dizziness—Prednisone—hematologic cancer	1.6e-05	4.52e-05	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—hematologic cancer	1.6e-05	4.52e-05	CcSEcCtD
Octreotide—Body temperature increased—Methotrexate—hematologic cancer	1.6e-05	4.52e-05	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.59e-05	4.51e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—JAK2—hematologic cancer	1.59e-05	9e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCND1—hematologic cancer	1.59e-05	9e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—JUN—hematologic cancer	1.59e-05	8.98e-05	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.59e-05	8.97e-05	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—AKT1—hematologic cancer	1.58e-05	8.95e-05	CbGpPWpGaD
Octreotide—Insomnia—Doxorubicin—hematologic cancer	1.58e-05	4.48e-05	CcSEcCtD
Octreotide—Paraesthesia—Doxorubicin—hematologic cancer	1.57e-05	4.45e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CASP3—hematologic cancer	1.57e-05	8.87e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—KRAS—hematologic cancer	1.57e-05	8.86e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IL2—hematologic cancer	1.57e-05	8.85e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—PIK3CA—hematologic cancer	1.56e-05	8.82e-05	CbGpPWpGaD
Octreotide—Dyspnoea—Doxorubicin—hematologic cancer	1.56e-05	4.41e-05	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—IL6—hematologic cancer	1.56e-05	8.81e-05	CbGpPWpGaD
Octreotide—Feeling abnormal—Epirubicin—hematologic cancer	1.56e-05	4.41e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—KRAS—hematologic cancer	1.56e-05	8.8e-05	CbGpPWpGaD
Octreotide—Somnolence—Doxorubicin—hematologic cancer	1.55e-05	4.4e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—MDM2—hematologic cancer	1.55e-05	8.79e-05	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Epirubicin—hematologic cancer	1.55e-05	4.38e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—CDKN1A—hematologic cancer	1.54e-05	8.71e-05	CbGpPWpGaD
Octreotide—Dyspepsia—Doxorubicin—hematologic cancer	1.54e-05	4.36e-05	CcSEcCtD
Octreotide—Vomiting—Prednisone—hematologic cancer	1.54e-05	4.35e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PTEN—hematologic cancer	1.54e-05	8.69e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—FGF2—hematologic cancer	1.53e-05	8.67e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCND1—hematologic cancer	1.53e-05	8.63e-05	CbGpPWpGaD
Octreotide—Rash—Prednisone—hematologic cancer	1.52e-05	4.31e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—JUN—hematologic cancer	1.52e-05	8.61e-05	CbGpPWpGaD
Octreotide—Dermatitis—Prednisone—hematologic cancer	1.52e-05	4.31e-05	CcSEcCtD
Octreotide—Decreased appetite—Doxorubicin—hematologic cancer	1.52e-05	4.3e-05	CcSEcCtD
Octreotide—Headache—Prednisone—hematologic cancer	1.51e-05	4.29e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PIK3CB—hematologic cancer	1.51e-05	8.55e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MTOR—hematologic cancer	1.51e-05	8.55e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3R1—hematologic cancer	1.51e-05	8.55e-05	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.51e-05	4.27e-05	CcSEcCtD
Octreotide—Fatigue—Doxorubicin—hematologic cancer	1.51e-05	4.27e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—MAPK8—hematologic cancer	1.5e-05	8.5e-05	CbGpPWpGaD
Octreotide—Urticaria—Epirubicin—hematologic cancer	1.5e-05	4.25e-05	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—AKT1—hematologic cancer	1.5e-05	8.48e-05	CbGpPWpGaD
Octreotide—Pain—Doxorubicin—hematologic cancer	1.5e-05	4.23e-05	CcSEcCtD
Octreotide—Constipation—Doxorubicin—hematologic cancer	1.5e-05	4.23e-05	CcSEcCtD
Octreotide—Body temperature increased—Epirubicin—hematologic cancer	1.49e-05	4.23e-05	CcSEcCtD
Octreotide—Abdominal pain—Epirubicin—hematologic cancer	1.49e-05	4.23e-05	CcSEcCtD
Octreotide—Hypersensitivity—Methotrexate—hematologic cancer	1.49e-05	4.21e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CDKN1A—hematologic cancer	1.48e-05	8.35e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PTEN—hematologic cancer	1.47e-05	8.33e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—JAK2—hematologic cancer	1.47e-05	8.31e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EP300—hematologic cancer	1.47e-05	8.29e-05	CbGpPWpGaD
Octreotide—Asthenia—Methotrexate—hematologic cancer	1.45e-05	4.1e-05	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—HRAS—hematologic cancer	1.44e-05	8.16e-05	CbGpPWpGaD
Octreotide—Feeling abnormal—Doxorubicin—hematologic cancer	1.44e-05	4.08e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—MAPK8—hematologic cancer	1.44e-05	8.15e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—PIK3CA—hematologic cancer	1.44e-05	8.14e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—AKT1—hematologic cancer	1.44e-05	8.13e-05	CbGpPWpGaD
Octreotide—Nausea—Prednisone—hematologic cancer	1.44e-05	4.06e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—MDM2—hematologic cancer	1.43e-05	8.11e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PIK3CA—hematologic cancer	1.43e-05	8.09e-05	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.43e-05	4.05e-05	CcSEcCtD
Octreotide—Pruritus—Methotrexate—hematologic cancer	1.43e-05	4.05e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—SRC—hematologic cancer	1.42e-05	8.06e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN1B—hematologic cancer	1.42e-05	8.02e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EP300—hematologic cancer	1.4e-05	7.94e-05	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—AKT1—hematologic cancer	1.4e-05	7.94e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MTOR—hematologic cancer	1.4e-05	7.89e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CB—hematologic cancer	1.4e-05	7.89e-05	CbGpPWpGaD
Octreotide—Hypersensitivity—Epirubicin—hematologic cancer	1.39e-05	3.94e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—CASP3—hematologic cancer	1.39e-05	7.86e-05	CbGpPWpGaD
Octreotide—Urticaria—Doxorubicin—hematologic cancer	1.39e-05	3.93e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—IL2—hematologic cancer	1.39e-05	7.85e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—VEGFA—hematologic cancer	1.39e-05	7.85e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—hematologic cancer	1.38e-05	7.82e-05	CbGpPWpGaD
Octreotide—Body temperature increased—Doxorubicin—hematologic cancer	1.38e-05	3.91e-05	CcSEcCtD
Octreotide—Abdominal pain—Doxorubicin—hematologic cancer	1.38e-05	3.91e-05	CcSEcCtD
Octreotide—Diarrhoea—Methotrexate—hematologic cancer	1.38e-05	3.91e-05	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—IL6—hematologic cancer	1.38e-05	7.81e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—STAT3—hematologic cancer	1.37e-05	7.77e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NRAS—hematologic cancer	1.37e-05	7.75e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SRC—hematologic cancer	1.37e-05	7.72e-05	CbGpPWpGaD
Octreotide—Asthenia—Epirubicin—hematologic cancer	1.36e-05	3.84e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—CCND1—hematologic cancer	1.35e-05	7.65e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—JUN—hematologic cancer	1.35e-05	7.64e-05	CbGpPWpGaD
Octreotide—Pruritus—Epirubicin—hematologic cancer	1.34e-05	3.79e-05	CcSEcCtD
Octreotide—Dizziness—Methotrexate—hematologic cancer	1.34e-05	3.78e-05	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—HRAS—hematologic cancer	1.33e-05	7.53e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—VEGFA—hematologic cancer	1.33e-05	7.52e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—HRAS—hematologic cancer	1.32e-05	7.48e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—STAT3—hematologic cancer	1.32e-05	7.45e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NRAS—hematologic cancer	1.31e-05	7.43e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MAPK3—hematologic cancer	1.31e-05	7.42e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN1B—hematologic cancer	1.31e-05	7.4e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN1A—hematologic cancer	1.31e-05	7.4e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PTEN—hematologic cancer	1.31e-05	7.39e-05	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—AKT1—hematologic cancer	1.3e-05	7.32e-05	CbGpPWpGaD
Octreotide—Diarrhoea—Epirubicin—hematologic cancer	1.29e-05	3.66e-05	CcSEcCtD
Octreotide—Hypersensitivity—Doxorubicin—hematologic cancer	1.29e-05	3.65e-05	CcSEcCtD
Octreotide—Vomiting—Methotrexate—hematologic cancer	1.28e-05	3.64e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—CASP3—hematologic cancer	1.28e-05	7.26e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IL2—hematologic cancer	1.28e-05	7.25e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MAPK8—hematologic cancer	1.28e-05	7.23e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MYC—hematologic cancer	1.28e-05	7.22e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—IL6—hematologic cancer	1.27e-05	7.21e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—AKT1—hematologic cancer	1.27e-05	7.21e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TGFB1—hematologic cancer	1.27e-05	7.2e-05	CbGpPWpGaD
Octreotide—Rash—Methotrexate—hematologic cancer	1.27e-05	3.61e-05	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—hematologic cancer	1.27e-05	3.6e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—IL6—hematologic cancer	1.27e-05	7.16e-05	CbGpPWpGaD
Octreotide—Headache—Methotrexate—hematologic cancer	1.27e-05	3.58e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—MAPK3—hematologic cancer	1.26e-05	7.12e-05	CbGpPWpGaD
Octreotide—Asthenia—Doxorubicin—hematologic cancer	1.25e-05	3.55e-05	CcSEcCtD
Octreotide—Dizziness—Epirubicin—hematologic cancer	1.25e-05	3.54e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—CCND1—hematologic cancer	1.25e-05	7.06e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—JUN—hematologic cancer	1.25e-05	7.05e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EP300—hematologic cancer	1.25e-05	7.04e-05	CbGpPWpGaD
Octreotide—Pruritus—Doxorubicin—hematologic cancer	1.24e-05	3.5e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—MYC—hematologic cancer	1.22e-05	6.92e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TGFB1—hematologic cancer	1.22e-05	6.9e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SRC—hematologic cancer	1.21e-05	6.85e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN1A—hematologic cancer	1.21e-05	6.83e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PTEN—hematologic cancer	1.21e-05	6.82e-05	CbGpPWpGaD
Octreotide—Vomiting—Epirubicin—hematologic cancer	1.2e-05	3.4e-05	CcSEcCtD
Octreotide—Nausea—Methotrexate—hematologic cancer	1.2e-05	3.4e-05	CcSEcCtD
Octreotide—Diarrhoea—Doxorubicin—hematologic cancer	1.2e-05	3.39e-05	CcSEcCtD
Octreotide—Rash—Epirubicin—hematologic cancer	1.19e-05	3.37e-05	CcSEcCtD
Octreotide—Dermatitis—Epirubicin—hematologic cancer	1.19e-05	3.37e-05	CcSEcCtD
Octreotide—Headache—Epirubicin—hematologic cancer	1.18e-05	3.35e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—VEGFA—hematologic cancer	1.18e-05	6.67e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—KRAS—hematologic cancer	1.18e-05	6.67e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MAPK8—hematologic cancer	1.18e-05	6.67e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—AKT1—hematologic cancer	1.18e-05	6.65e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—STAT3—hematologic cancer	1.17e-05	6.61e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—AKT1—hematologic cancer	1.17e-05	6.61e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NRAS—hematologic cancer	1.17e-05	6.59e-05	CbGpPWpGaD
Octreotide—Dizziness—Doxorubicin—hematologic cancer	1.16e-05	3.27e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—EP300—hematologic cancer	1.15e-05	6.5e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—KRAS—hematologic cancer	1.13e-05	6.4e-05	CbGpPWpGaD
Octreotide—Nausea—Epirubicin—hematologic cancer	1.12e-05	3.18e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—SRC—hematologic cancer	1.12e-05	6.32e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MAPK3—hematologic cancer	1.12e-05	6.31e-05	CbGpPWpGaD
Octreotide—Vomiting—Doxorubicin—hematologic cancer	1.11e-05	3.15e-05	CcSEcCtD
Octreotide—Rash—Doxorubicin—hematologic cancer	1.1e-05	3.12e-05	CcSEcCtD
Octreotide—Dermatitis—Doxorubicin—hematologic cancer	1.1e-05	3.12e-05	CcSEcCtD
Octreotide—Headache—Doxorubicin—hematologic cancer	1.1e-05	3.1e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—VEGFA—hematologic cancer	1.09e-05	6.16e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MYC—hematologic cancer	1.09e-05	6.14e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CA—hematologic cancer	1.08e-05	6.13e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TGFB1—hematologic cancer	1.08e-05	6.12e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—STAT3—hematologic cancer	1.08e-05	6.1e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NRAS—hematologic cancer	1.08e-05	6.08e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—hematologic cancer	1.05e-05	5.93e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CA—hematologic cancer	1.04e-05	5.88e-05	CbGpPWpGaD
Octreotide—Nausea—Doxorubicin—hematologic cancer	1.04e-05	2.94e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—MAPK3—hematologic cancer	1.03e-05	5.82e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TP53—hematologic cancer	1.01e-05	5.68e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KRAS—hematologic cancer	1e-05	5.67e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—HRAS—hematologic cancer	1e-05	5.67e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MYC—hematologic cancer	1e-05	5.67e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TGFB1—hematologic cancer	9.99e-06	5.65e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—HRAS—hematologic cancer	9.61e-06	5.44e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IL6—hematologic cancer	9.6e-06	5.43e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KRAS—hematologic cancer	9.26e-06	5.23e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PIK3CA—hematologic cancer	9.22e-06	5.21e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IL6—hematologic cancer	9.2e-06	5.2e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—hematologic cancer	8.92e-06	5.04e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—AKT1—hematologic cancer	8.85e-06	5.01e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—HRAS—hematologic cancer	8.53e-06	4.82e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CA—hematologic cancer	8.51e-06	4.81e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—AKT1—hematologic cancer	8.49e-06	4.8e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—hematologic cancer	8.23e-06	4.65e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IL6—hematologic cancer	8.16e-06	4.61e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HRAS—hematologic cancer	7.87e-06	4.45e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IL6—hematologic cancer	7.53e-06	4.26e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—AKT1—hematologic cancer	7.53e-06	4.26e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKT1—hematologic cancer	6.95e-06	3.93e-05	CbGpPWpGaD
